Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension

  • Review Articles
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Losartan potassium is the first of a new class of orally active antihypertensive drugs which antagonise the action of angiotensin (AT) II at the AT1 receptor subtype. Losartan potassium is converted by the liver to the active metabolite E-3174, which is a more potent antagonist at the AT1 receptor. E-3174 is responsible for most of the pharmacological effects of losartan potassium, and its long half-life contributes to the extended duration of action of the drug.

Losartan potassium is effective as a once-daily antihypertensive agent. In mild to moderate hypertension, losartan potassium has similar efficacy to enalapril, atenolol and felodipine extended release. When losartan potassium is combined with hydrochlorothiazide there is a further reduction in blood pressure.

Losartan potassium is well tolerated in mild, moderate and severe essential hypertension, with dizziness being reported as the only drug-related adverse effect. The overall rate of patient withdrawal from therapy due to adverse experiences with losartan potassium is lower (2.3%) than that of placebo (3.7%). First-dose hypotension is uncommon, perhaps due to the slower onset of action of the drug, and cough does not appear to be a significant problem.

A number of areas concerning the safety and efficacy of losartan potassium remain to be clarified. In particular, long term tolerability studies are needed; cough only became apparent as an adverse effect of ACE inhibitors after 3 to 4 years of use. Postmarketing surveillance has shown that angioedema, a rare but life-threatening adverse effect of ACE inhibitors, also occurs with losartan potassium. Further data are needed on the use of losartan potassium in patients with renal impairment before accepting the recommendation that dosage adjustment is not necessary. The pharmacokinetics and pharmacodynamics of losartan potassium in patients with hepatic disease also require further investigation.

Losartan potassium increases uric acid secretion and lowers plasma uric acid levels, which may be of benefit when losartan potassium is combined with a thiazide diuretic, but which may otherwise lead to uric acid stone formation and possibly to nephropathy.

Simple control of blood pressure is no longer an adequate goal in the management of hypertension. Any new antihypertensive agent should also reduce cardiovascular events, prevent or cause regression of end-organ damage such as left ventricular hypertrophy, atherosclerosis and renal failure, and should not impair quality of life. Such data on losartan potassium are not currently available.

Losartan potassium is likely to be used in patients who are intolerant of ACE inhibitors, but its future in the management of hypertension will depend on long term tolerability studies and data on its effects beyond simple blood pressure control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Johnston CI, Burrell LM. Evolution of blockade of the renin angiotensin system. J Hum Hypertens 1995; 9: 375–80

    PubMed  CAS  Google Scholar 

  2. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995 Nov; 346: 1403–7

    Article  PubMed  CAS  Google Scholar 

  3. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonist. Arch Int Med 1995; 155: 1361–8

    Article  CAS  Google Scholar 

  4. Burrell LM, Johnston CI. Beyond ACE inhibition — new approaches to the understanding and management of hypertension. Med J Aust 1995; 162: 659–62

    PubMed  CAS  Google Scholar 

  5. Abdelrahman A, Burrell LM, Johnston CI. Blockade of the renin angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens 1993; 11: S23–6

    Article  CAS  Google Scholar 

  6. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–51

    PubMed  CAS  Google Scholar 

  7. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51:513–21

    Article  PubMed  CAS  Google Scholar 

  8. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP 3174 in humans. Clin Pharmacol Ther 1995 Dec; 58: 611–9

    Article  Google Scholar 

  9. Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995 Feb; 23 (2): 207–15

    PubMed  CAS  Google Scholar 

  10. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996 May; 51 (5): 820–45

    Article  PubMed  CAS  Google Scholar 

  11. Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992; 5: 19A-20A

    Google Scholar 

  12. Weber MA, Byyny RL, Pratt J, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Int Med 1995 Feb 27; 155:405–11

    Article  CAS  Google Scholar 

  13. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28–32

    PubMed  CAS  Google Scholar 

  14. Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041–4

    PubMed  CAS  Google Scholar 

  15. Dunlay MC, Fitzpatrick V, Chyysant S, et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995 Nov; 9: 861–7

    PubMed  CAS  Google Scholar 

  16. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995 Jun; 25: 1345–50

    Article  PubMed  CAS  Google Scholar 

  17. Tikkanen I, Omvik P, Jensen H. Comparison of the angiotensin II antagonist, losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13; 1343–51

    Article  PubMed  CAS  Google Scholar 

  18. Mallion J-M, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate hypertension. J Hypertension 1995; 13 Suppl. 1: S35–41

    Article  CAS  Google Scholar 

  19. Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination therapy with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14: 263–70

    Article  PubMed  CAS  Google Scholar 

  20. Dahlof B, Keller SE, Makris L, et al Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8 (6): 578–83

    Article  PubMed  CAS  Google Scholar 

  21. Chan JC, Critchley JA, Lappe JT, et al. Randomised, doubleblind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995 Sep; 9: 765–71

    PubMed  CAS  Google Scholar 

  22. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996 Feb 12; 156: 278–85

    Article  PubMed  CAS  Google Scholar 

  23. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–7

    Article  PubMed  CAS  Google Scholar 

  24. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995 Apr 15; 75: 793–5

    Article  PubMed  CAS  Google Scholar 

  25. Lacourciere Y, Brunner H, Irwin R, et al., Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994 Dec; 12: 1387–93

    PubMed  CAS  Google Scholar 

  26. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995 Dec 7; 333: 1572

    Article  PubMed  CAS  Google Scholar 

  27. Gansevoort RT, De Zeeuw D, Shahinfar S, et al. Effects of angiotensin II receptor antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 Suppl. 2: S37–42

    CAS  Google Scholar 

  28. Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II receptor antagonist in patients with essential hypertension. Am J Hypertens 1994; 7: 1035–40

    PubMed  CAS  Google Scholar 

  29. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995 Jan; 25: 37–46

    Article  PubMed  CAS  Google Scholar 

  30. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney Int 1994; 45: 861–7

    Article  PubMed  CAS  Google Scholar 

  31. Kasiske B, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Int Med 1993; 118: 129–38

    PubMed  CAS  Google Scholar 

  32. Lewis EJ, Hunsicker LG, Bain RP, et al., Collaborative Study Group. The effect of angiotensin converting enzyme inhibitors in diabetic nephropathy. New Engl J Med 1993; 329: 1456–62

    Article  PubMed  CAS  Google Scholar 

  33. Urata H, Boehm K, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269–81

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austin and Repatriation Medical Centre, University of Melbourne, Heidelberg, 3084, Victoria, Australia

    Louise M. Burrell

Authors
  1. Louise M. Burrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louise M. Burrell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burrell, L.M. A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension. Drug-Safety 16, 56–65 (1997). https://doi.org/10.2165/00002018-199716010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199716010-00004

Keywords

Search

Navigation